Analysts expect Cellectis SA (NASDAQ:CLLS) to report ($0.67) earnings per share for the current quarter, Zacks reports. Four analysts have provided estimates for Cellectis’ earnings, with the highest EPS estimate coming in at ($0.53) and the lowest estimate coming in at ($0.77). Cellectis reported earnings per share of ($0.39) in the same quarter last year, which suggests a negative year over year growth rate of 71.8%. The business is scheduled to issue its next quarterly earnings report on Monday, May 6th.
On average, analysts expect that Cellectis will report full year earnings of ($2.90) per share for the current financial year, with EPS estimates ranging from ($3.55) to ($2.14). For the next financial year, analysts forecast that the company will report earnings of ($2.11) per share, with EPS estimates ranging from ($2.82) to ($1.42). Zacks’ EPS calculations are an average based on a survey of research firms that follow Cellectis.
Cellectis (NASDAQ:CLLS) last released its quarterly earnings results on Monday, March 11th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.14. Cellectis had a negative net margin of 362.48% and a negative return on equity of 18.63%. The firm had revenue of $3.08 million during the quarter, compared to analyst estimates of $7.46 million.
Cellectis stock opened at $19.58 on Monday. Cellectis has a 52-week low of $15.34 and a 52-week high of $35.08.
Large investors have recently added to or reduced their stakes in the company. Financial Gravity Companies Inc. bought a new stake in shares of Cellectis in the 4th quarter valued at $71,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its stake in shares of Cellectis by 37.6% in the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,545 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 1,787 shares in the last quarter. Two Sigma Investments LP bought a new stake in shares of Cellectis in the 4th quarter valued at $180,000. KBC Group NV increased its stake in shares of Cellectis by 22.9% in the 4th quarter. KBC Group NV now owns 14,266 shares of the biotechnology company’s stock valued at $238,000 after acquiring an additional 2,661 shares in the last quarter. Finally, Squarepoint Ops LLC increased its stake in shares of Cellectis by 28.3% in the 4th quarter. Squarepoint Ops LLC now owns 16,455 shares of the biotechnology company’s stock valued at $274,000 after acquiring an additional 3,626 shares in the last quarter. Institutional investors own 27.61% of the company’s stock.
Cellectis Company Profile
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Featured Story: What is Blockchain?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.